Abstract-The recent discovery of additional alternative spliced FLT1 transcripts encoding novel soluble (s)FLT1 protein isoforms complicates both the predictive value and functional implications of sFLT1 in preeclampsia. We investigated FLT1 expression levels and splicing patterns in placentas of normotensive and preeclamptic women, and established the tissue specificity of all FLT1 transcript variants. mRNA levels of sFLT1 splice variants were determined by real-time polymerase chain reaction in 21 normal human tissues and placental biopsies from 91 normotensive and 55 preeclamptic women. Cellular localization of placental FLT1 expression was established by RNA in situ hybridization. Of all tissues investigated, placenta has by far the highest FLT1 mRNA expression level, mainly localized in the syncytiotrophoblast layer. More than 80% of placental transcripts correspond to sFLT1_v2. Compared with normotensive placenta, preeclamptic placenta has Ϸ3-fold higher expression of all FLT1 transcript variants (PϽ0.001), with a slight shift in favor of sFLT1_v1. Although to a lesser degree, transcript levels are also increased in placenta from normotensive women that deliver a small for gestational age neonate. We conclude that sFLT isoform-specific assays could potentially improve the accuracy of current sFLT1 assays for the prediction of preeclampsia. However, placental FLT1 transcript levels are increased not only in preeclampsia but also in normotensive pregnancy with a small for gestational age fetus. This may indicate a common pathway involved in the development of both conditions but complicates the use of circulating sFLT1 protein levels for the prediction or diagnosis of preeclampsia alone. (Hypertension.
H ypertension-related disorders are a major cause of pregnancy complications. Preeclampsia in particular, defined as new-onset hypertension in combination with proteinuria after 20 weeks of gestation, is a leading cause of both maternal and fetal mortality and morbidity. 1 Because preeclampsia is a complex disease involving multiple organs, it has been difficult to clearly assign molecular pathways involved in the etiology. Consequently, proper targets for the development of early biomarkers and prophylaxis are scarce.
Although the exact model how preeclampsia develops is still a matter of debate, preeclampsia is thought to originate from abnormal placentation followed by a release of placenta-produced factors into the maternal circulation. These in turn provoke dysfunction of the maternal endothelium, resulting in the preeclamptic clinical symptoms. 2, 3 The vascular endothelial growth factor (VEGF) ligands/receptors play an essential role in both normal and pathological functioning of the endothelium 4 and have been implicated in the development of preeclampsia. In particular, the soluble truncated version of VEGF receptor 1 (sFLT1) has been shown to be markedly elevated in preeclamptic women. [5] [6] [7] sFLT1 mRNA is generated by alternative splicing of the FLT1 gene. As a result, sFLT1 protein contains only the ligand binding domain of the VEGF receptor 1 and a small unique 31-aa C-terminal tail but lacks the membrane spanning and intracellular tyrosine kinase domain of the fulllength receptor. 8 The current concept of the role of sFLT1 in preeclampsia is that it traps VEGF and placenta growth factor, thereby lowering free circulating levels of these factors below a critical threshold.
In addition to the interest in the functional role of sFLT1/ VEGF in preeclampsia, and hence their therapeutic potential, much research has been focused on the biomarker capacity of sFLT1 in predicting preeclampsia. Within studies, circulating levels of sFLT1 are elevated, and placenta growth factor levels are reduced in preeclamptic pregnancies compared with normal pregnancies weeks before overt clinical symptoms arise, 9, 10 but comparison of key studies shows marked differences in absolute levels measured. 11 The role of sFLT1 in preeclampsia has recently become more complicated by the discovery that multiple sFLT1 isoforms exist. In addition to the originally described sFLT1 8 (hereafter called sFLT_v1), a second sFLT1 isoform (sFLT1_v2) has recently been characterized. 12, 13 Similar to sFLT1_v1, the sFLT_v2 protein is also a soluble truncated version of the full-length VEGF receptor 1 but with a 28-aa unique C terminus. In addition, 2 currently less well-characterized sFLT1 splice variants, sFLT_v3 and sFLT_v4, with a 13-aa and 31-aa unique C terminus, respectively, have been reported. 14 Although investigated in a very limited number of patients, these 3 novel sFLT1 splice variants, and also the transmembrane variant (tmFLT1), seem upregulated in preeclamptic women. 5, [12] [13] [14] [15] In this study, we aim to establish the placental contribution of all individual FLT1 transcript variants to the total increased circulating sFLT1 protein pool that is observed in preeclampsia to further specify their potential use as biomarkers. For that purpose, we analyzed the tissue specificity of FLT1 transcript variants and determined their levels of expression in a human mRNA tissue panel and a large series of normotensive and preeclamptic placental biopsies.
Methods
For expanded methods, please see the online supplement http:// hyper.ahajournals.org.
Patients
Preeclampsia and HELLP syndrome were defined by National Heart, Lung and Blood Institute Working Group criteria and those proposed by Sibai. 1, 16 Blood pressure was manually measured in the sitting position at the right upper arm. Diastolic blood pressure was determined at Korotkoff sound V. Patients with baseline hyperten- sion or renal disease were excluded. Small for gestational age (SGA) was defined as a birth weight below the 10th percentile according to the Dutch birth weight percentiles. Placental insufficiency was defined as raised pulsatility index of the umbilical artery (Ͼ95th percentile) combined with either a lowered pulsatility index of the middle cerebral artery (Ͻ5th percentile) or an increased impedance to flow in the uterine arteries (early diastolic notching). Doppler studies were performed when clinically indicated by the treating obstetrician. Healthy, normotensive pregnant women were included as controls. The clinical characteristics of included individuals are listed in supplemental Table I .
Tissue Preparation and Real-Time Quantitative Polymerase Chain Reaction
The use of clinical data and placenta material for this study was approved by the institutional review board of the Academic Medical Center. Samples were collected from 91 normotensive and 55 preeclamptic pregnant women as described 17 (Table 1; supplemental  Table I ). RNA was isolated and reverse transcribed, and quantitative real-time polymerase chain reaction was performed on a LightCycler 480 system (Roche).
In Situ Hybridizations
RNA in situ hybridization was essentially performed as described. 18 Probes corresponded to nucleotides 2968 to 3361 (Genbank NM_002019.4, tmFLT1), 2208 to 2297 (Genbank BC039007.1, sFLT1_v1), and 2538 to 2620 (Genbank NM_001160030.1, sFLT1_v2).
Results

Tissue-Specific Expression of FLT1 Splice Variants
To investigate both the absolute and relative expression levels for the different FLT1 transcripts, we analyzed 21 human tissues by real-time quantitative polymerase chain reaction ( Figure 1A ). Absolute levels of total FLT1 mRNA in placenta are Ն40-fold higher than in any of the other human tissues studied. Although in most tissues, the majority of transcripts encode the transmembrane form of FLT1, in placenta, 95% of all FLT1 transcripts represent the alternative splice variants encoding truncated soluble receptors. sFLT1_v2 is the most prominent transcript variant (Ͼ80% of all placental FLT1 transcripts) and is highly placenta specific, with some residual (Ն600-fold lower) expression in other tissues. Expression of the sFLT1_v3 and sFLT1_v4 splice variants is relatively low in all tissues, and sFLT1_v3 levels are below detection level in most.
To evaluate the contribution of maternal, respectively placental/fetal endothelial cells, (known to prominently express FLT1 19 ), to the total FLT1 pool, we analyzed FLT1 transcript levels in early passage primary endothelial cells (human brain microvascular endothelial cells and human umbilical vein endothelial cells). The absolute total FLT1 mRNA expression level in human brain microvascular endothelial cells and human umbilical vein endothelial cells is much lower (Ͻ8%) than in placenta and sFLT1_v1 is the most abundant splice product. The sFLT1_v2 fraction is only 23%, respectively 6% (compared with the Ͼ80% sFLT1_v2 mRNA in placenta). Compared with the other tissues studied, both placenta tissue and human brain microvascular endothelial cells have a relatively high fraction of FLT1 transcripts encoding soluble receptor forms (94% and 75%, respectively).
RNA in situ hybridization with variant-specific FLT1 probes demonstrates an intense signal in the syncytiotrophoblast layer for all transcripts tested ( Figure 1B) . Compared with the syncytiotrophoblast signal, vascular endothelial cells were also clearly positive for sFLT1_v1 expression, whereas tmFLT1 and sFLT1_v2 signals were weak or absent.
FLT1 Splice Variants in Normotensive and Preeclamptic Placentas
We determined expression levels of all 5 FLT1 transcripts in 91 placentas from normotensive pregnancies and 55 placentas from preeclamptic pregnancies ( Table 1; supplemental Table  I ). In preeclamptic placenta, FLT1 transcript levels are nearly 4-fold increased, with a statistically significant upregulated expression of all 5 transcript variants, including the lowexpressed variants sFLT1_v3 and sFLT1_v4 (Table 2) . Strikingly, in preeclamptic placenta, the splicing process seems to favor splicing toward sFLT1_v1 at the expense of the other Values are median normalized transcripts levels (interquartile range). Ratio is defined as transcript level divided by total FLT1 transcript level (interquartile range). *Group differences were tested with the Mann-Whitney U test.
splice variants, especially tmFLT1. Consequently, there is a shift toward the soluble FLT encoding transcripts in preeclampsia at the expense of the transmembrane version (Pϭ0.029).
FLT1 transcript levels in normotensive and preeclamptic placentas do not correlate with gestational age at delivery (Figure 2A ; data not shown). There is a positive correlation with the highest measured diastolic blood pressure as shown in Figure 2B . sFLT1_v1 levels correlate most strongly with diastolic blood pressures. We observe no significant correlation between FLT1 transcript levels and the amount of proteinuria (data not shown).
FLT1 Transcript Levels in Relation to Fetal Growth
Analysis of the association between fetal growth and FLT1 transcript levels in placentas of normotensive pregnancies showed that placentas from SGA (nϭ11) neonates FLT1 mRNA expression is significantly increased compared with those from newborns with a weight appropriate for their gestational age, defined as neonatal weight between p10 and p90 on the Dutch neonatal growth charts (nϭ74; Figure 3 ). This SGA-specific increase in placental FLT1 expression is restricted to normotensive pregnancies and is not observed in preeclamptic pregnancies. Compared with all preeclamptic placentas, the tmFLT1 and sFLT1_v2 mRNA levels in normotensive SGA placentas do not differ significantly (data not shown). Only the normotensive SGA placental sFLT1_v1 mRNA levels are significantly lower (Pϭ0.047) compared with preeclamptic placentas. Of the 11 women who delivered an SGA neonate after a normotensive pregnancy, only 1 had an aberrant umbilical arterial Doppler velocimetry combined with lowered pulsatility index of the middle cerebral artery, indicative of intrauterine growth restriction caused by placental insufficiency. Six showed a normal Doppler pattern, whereas for 4 cases, no Doppler data were available (supplemental Table I ).
In preeclamptic pregnancies with a confirmed normal umbilical Doppler velocimetry, there is still the large increase of placental FLT1 transcripts visible compared with normotensive pregnancies (supplemental Table III ).
Discussion
In our study, we report placental expression and splicing of the FLT1 gene in a large series of normotensive and preeclamptic pregnancies and in pregnancies complicated by SGA neonates. We also compare FLT1 expression levels and splicing pattern in placenta with a large series of other human tissues, demonstrating that compared with other human tissues, absolute levels of all FLT1 splice variants in placenta are extremely high. Second, there is a general increased FLT1 transcription, or alternatively, a general increased FLT1 mRNA stability in preeclamptic placentas compared with normotensive placentas. In addition to the previously reported elevated sFLT1 (sFLT1_v1) mRNA levels, levels of the transmembrane VEGF receptor encoding transcript (tmFLT1) and the newly described sFLT1 transcript variants sFLT1_v2, _v3, and _v4 are Ͼ2-fold increased in placenta of preeclamptic women compared with placenta of normotensive women. However, in addition, SGA placentas of normotensive women show a preeclampsia-like pattern of increased FLT1 transcripts.
Apart from this increased transcription/stability, the process of alternative splicing also seems altered in case of preeclamptic pregnancy, with an increased favor toward the formation of the sFLT1_v1 splice variant. The signals triggering the increase of expression and change of relative splicing patterns of FLT1 mRNA in pathological placentas compared with placental tissue from normal pregnancies are not fully established. Both transcription/stability and the process of alternative splicing are altered in case of preeclamptic pregnancy and placental hypoxia, commonly re- garded as an important contributor to the development of preeclampsia, is a known driving force for FLT1 transcription, 20 as well as the preferential splicing of sFLT1_v1 variant. 21, 22 There is no correlation between placental FLT1 transcript levels and gestational age in either normotensive or hypertensive pregnancies, indicating that the reported increase of maternal circulating sFLT1 protein levels as gestation advances during the last trimester 7, 23 are attributable to placental growth and the concomitant increased number of cells that produce sFLT1.
A striking observation is the combination of very high levels of FLT1 mRNA in placenta compared with all other tissues investigated, and the fact that Ͼ90% of these transcripts encode a soluble VEGF receptor protein, whereas in most other tissues, the majority of transcripts encode the transmembrane VEGF receptor protein. We can only speculate on why the placenta generates such high amounts of FLT1 mRNA and most likely produces most of its FLT1 protein as the truncated soluble VEGF receptor. Mouse studies indicate that trophoblast-derived tmFLT1 and sFLT1 have no obvious function in placental development, 24 and in mouse placenta, 98% of the FLT1 protein is the soluble VEGF receptor. 25 Thus, the purpose of placental FLT1 transcription may well be the production of truncated soluble VEGF receptor with a systemic, pregnancy-specific function in the maternal circulation.
Our data show that sFLT1_v2 is by far the major transcript variant in the placenta. Within placenta, sFLT1_v2 mRNA is mainly, if not exclusively, expressed in the syncytiotrophoblast layer. Because only Ϸ15% of the placental sFLT1 mRNA pool is formed by sFLT1-v1 in combination with only marginally expressed sFLT1_v3 and sFLT1_v4 (Ͻ1% of the total sFLT1 transcripts), this implies that Ϸ85% of the sFLT1 mRNA produced by the placenta is sFLT1_v2. This situation is highly placenta specific because none of the other tissues investigated express this typical splice variant pattern. The low-level sFLT1_v2 mRNA in other tissues may originate from incorporated endothelial cells, which also express sFLT1_v2 mRNA.
On the basis of our study, we cannot elucidate whether placental sFLT1 mRNA levels (with relatively high levels of sFLT1_v2 and relatively low levels of sFLT1_v1) are directly related to the amount of sFLT1 protein secreted into the maternal circulation. Antibodies raised against the C-terminal tail specific for the sFLT1_v2 transcript show that this protein is indeed the predominant sFLT1 isoform present in placenta extract and the circulation during pregnancy. 12 In another study, 26 in which sFLT1 isoforms present in maternal plasma were size separated, the size of the major sFLT1 isoform corresponds to that of sFLT_v2, whereas the minor isoform corresponds to sFLT_v1. Together, these observations suggest that the sFLT_v1 and _v2 mRNA levels relate to the sFLT1 proteins that are measured during pregnancy in the maternal circulation.
The currently available sFLT1 antibodies, mostly raised against a protein domain shared by all FLT1 isoforms, have had only limited diagnostic utility in predicting preeclampsia. 27 At the protein level, sFLT1 isoforms differ only in their C-terminal amino acid tail, which has had until now no resemblance to any known functional peptide domain. This indicates that the sFLT1 isoforms are functionally identical. Splice form-specific antibodies might improve the clinical strength of sFLT level in predicting preeclampsia, and sFLT1_v2-specific antibodies could potentially be less troubled by sFLT proteins secreted by nonplacental tissues.
Literature on the relationship between fetal growth and sFLT1 levels is conflicting, which is partly because of the nonsystematic use of the diagnostic terms SGA, fetal growth restriction, and intrauterine growth restriction. Patient groups consisting of the more severe SGA (defined by either abnormal Doppler, birth weight below the third percentile, or delivered at early gestational age) appear to have increased sFLT1 protein levels in the maternal circulation, 6,23,28 -30 whereas those with milder SGA do not show the higher than normal maternal sFLT1 levels. 23,28 -32 In the current study, we defined SGA as a birth weight below the 10th percentile, corrected for gestational age at delivery, parity, and gender. Our data demonstrate increased FLT1 mRNA levels in placentas from normotensive SGA newborns compared with appropriate for their gestational age newborns. It would be logical to assume that placental dysfunction characterized by increased sFLT1 levels may relate to either SGA fetuses or preeclampsia. However, one would expect that this holds true especially for those SGA neonates with signs of placental insufficiency like aberrant Doppler waveforms during pregnancy. We did not find evidence for this in our patients. It could be that the placenta "senses" fetal nutritional problems, and high FLT1 levels are a placental signal to increase uterine blood flow. 33 This mechanism can be activated anytime during pregnancy, which in case of our normotensive SGA pregnancies with normal Doppler, might be relatively late. As a consequence, the systemic endothelial damage and preeclamptic clinical symptoms may not (yet) be overt in these cases. Although in our population, the placental FLT1 transcript levels correlate with increased maternal blood pressure, women who deliver an SGA infant have similar increased FLT transcript levels without sign of a systemic endothelial dysfunction.
Perspectives
The current data demonstrate that all FLT1 transcript variants are increased in preeclamptic placentas compared with normotensive placentas. The complex patterns of FLT1 transcription and splicing in preeclamptic and SGA placentas obscure an exact relationship between circulating FLT1 levels and gestational hypertensive disease. Based on placenta specificity and levels of expression, methods that would measure specific sFLT1 isoforms in the maternal circulation may perform better in predictive or diagnostic assays for preeclampsia than the currently used FLT1 assays.
growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 
Expanded Methods
Patients. Preeclampsia was defined by two systolic blood pressure (BP) measurements of ≥140 mmHg, or diastolic BP measurements of ≥90 mmHg, at least 6 hours apart after 20 weeks' gestation in a previously normotensive patient in combination with new-onset proteinuria (> 0.3 g / 24-hour or at least >1+ on protein dipstick when urine could not be collected for 24 hours) 1 . BP was manually measured in the sitting position at the right upper arm. Diastolic BP was determined at Korotkoff sound V. Patients with baseline hypertension or renal disease were excluded. Small for gestational age (SGA) was defined as a birth-weight below the 10 th percentile according to the Dutch birth weight percentiles. The appropriate chart was chosen based on parity and gender of the baby (http://www.perinatreg.nl/). Placental insufficiency was suspected when the pulsatility index of the umbilical artery was raised (>95 Table S1 .
Tissue preparation and RT-qPCR.
The use of clinical data and placenta material for this study was approved by the institutional review board of the Academic Medical Center. Samples were collected from 91 normotensive, and 55 preeclamptic pregnant women (Table 1 and  Table S1 ).
Placental biopsies from a macroscopically viable (non-infarcted) central cotyledon from the maternal side were obtained immediately after delivery and stored either in RNAlater (Ambion) or snap frozen in liquid nitrogen 3 . RNA was isolated on a MagNA Pure LC RNA Isolation Kit High Performance (Roche), and reverse transcribed using AMV First Strand cDNA Synthesis Kit for reverse transcription (RT)-PCR (Roche). Quantitative realtime PCR (qPCR) was performed on a LightCycler 480 system (Roche) according to the manufacturers protocol with reaction mixtures containing 2.5 µl cDNA, 0.4 μmol/L of each primer (Invitrogen), 100 nmol/L UPL probe (Roche) and 5 µl Absolute qPCR mix (Thermo Scientific) in a total volume of 10 µl. Primers were designed using the Roche Universal ProbeLibrary Assay Design Center (Table S2 ). Data were analyzed and quantified, using the second derivative maximum for Cp determination, with the LightCycler 480 software 1.5.0 (Roche). For the human tissue panel, total RNA was obtained from Clontech, or isolated from Human Brain Microvascular Endothelial Cells (HBMECs) (3HBiomedical) using RNeasy kit and QiaCUBE (Qiagen). cDNA from primary Human Umbilical Vein Endothelial Cells (HUVEC) was provided by Anita Böing, Department of Clinical Chemistry, Academic Medical Center, Amsterdam.
Statistical analysis. Transcript level data deviated significantly from normality by the Kolmogorov-Smirnov test, even after log transformation. Group differences were tested using the Mann-Whitney U test, and correlations were analyzed by Spearman's rank correlation. In the box and whiskers plots, the box represents the interquartile range and the median, while the whiskers indicate the maximum and minimum values that are between 1.5 and 3 times the interquartile range. P-values < 0.05 were considered statistically significant. SPSS 16 Table S1 . normotensive control unknown  no  no  no  no  35+4  vaginal  male 2785 50-80  40  1  0  61  normotensive control  94 †  no  unknown unknown  no  29+3  primary cesarean section  female 930  20-50  29  3  2  62  normotensive control  75  no  no  yes  no  27+2  vaginal, breech  male  980  50-80  18  63  1.74  20.8 1  0  63  normotensive control  70  no  no  yes  no  28+6  vaginal  female 1150 50-80  26  1  0  64  normotensive control  65  no  no  yes  no  29+3  vaginal  male 1263 20-50  39  53  1.75  17.3 2  1  65  normotensive control  75  no  no  no  yes  no  1.35 and 0.98  positive  no notches  34+5  primary cesarean section  male 2280 20-50  37  1  0  66  normotensive control  68  no  8  yes  no  30+6  vaginal  male 1770 80-84  16  1  0  67  normotensive control  65  no  8 . ISH was performed with antisense probes for tmFLT1, sFLT1_v1, and sFLT1_v2 on sections of both normotensive and preeclamptic (PE) placentas of different gestational age. Magnification 100x, bar corresponds to 80 M.
Clinical data of included individuals
59 normotensive control 65 no no no no 41+6 vaginal male 3540 16-20 29 53 1.51 23.2 2 1 60
